NEW YORK, July 11 – Protein Design Labs has agreed to license the Rosetta Resolver gene expression data analysis system from Rosetta Inpharmatics and exclusive distributor Agilent Technologies, the companies said Wednesday.
Financial details were not disclosed.
The Resolver system accepts data from a wide variety of expression profiling formats, including Affymetrix GeneChip and Agilent DNA microarrays, and applies proprietary error models to calculate statistics on gene expression data. Rosetta, based in Kirkland, Wash., released version 2.0 of the system in the first quarter of 2001.
Protein Design Labs, of Fremont, Calif., develops “humanized” monoclonal antibodies, mouse or rat antiobodies that are modified for therapeutic applications in humans. Max Vasquez, director of target validation at Protein Design Labs, said in a statement that the company would use the Resolver system in its antibody target identification and validation programs.
In May, Merck acquired Rosetta for $620 million in stock, but said that Rosetta would continue to operate the Resolver business as a separate cost center. Rosetta has licensed its Resolver system to a number of pharmaceutical and biotechnology companies, including GlaxoSmithKline, Biogen, Immunex, Paradigm Genetics, and Merck.